Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Toronto
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

QLT:CN

4.8400 CAD 0.0400 0.83%

As of 14:29:50 ET on 03/27/2015.

Snapshot for QLT Inc (QLT)

Open: 4.7200 Day's Range: 4.7200 - 4.8400 Volume: 2,850
Previous Close: 4.8000 52wk Range: 3.9100 - 7.4500 1-Yr Rtn: -22.19%

Stock Chart for QLT

No chart data available.
  • QLT:CN 4.8400
  • 1D
  • 1M
  • 1Y
4.8000
Interactive QLT Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for QLT

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPTSX -
Earnings Per Share (USD) (ttm) -0.4600
Est. EPS (USD) (12/2015) -0.2500
Est. PEG Ratio -
Market Cap (M CAD) 248.05
Shares Outstanding (M) 51.25
30 Day Average Volume 6,688
Price/Book (mrq) 1.2556
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend (USD) 3.9153
Dividend Ex-Date 06/28/2013
5 Year Dividend Growth -
Next Earnings Announcement 04/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for QLT

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for QLT

QLT Inc. develops and commercializes pharmaceutical products for use in photodynamic therapy, the use of light activated drugs to treat disease. The Company's lead drug, Visudyne, is marketed by Novartis AG, and is used in the treatment of the wet form of age-related macular degeneration.

Jason M AryehChairmanGeoffrey F Cox "Geoff"Interim CEO
Glen IbbottInterim CFO/VP:Finance
More Company Profile & Key Executives for QLT

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil